Tilray Gets Second Approval For Medical Marijuana Extract In Portugal
Portfolio Pulse from Nina Zdinjak
Tilray Brands, Inc. (NASDAQ:TLRY) has received its second approval for a medical marijuana extract in Portugal, specifically for its Tilray Oral Solution THC10:CBD10. This follows previous approvals for other cannabis products in Portugal and Germany. Tilray's shares were trading 1.07% lower at $1.87 during Wednesday’s pre-market session.

July 24, 2024 | 1:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tilray Brands, Inc. has received its second approval for a medical marijuana extract in Portugal, which could enhance its market presence in Europe. However, shares were trading 1.07% lower at $1.87 during Wednesday’s pre-market session.
The approval of a new medical marijuana extract in Portugal is a positive development for Tilray, potentially expanding its market and product offerings in Europe. Despite this, the stock was trading lower in the pre-market session, which could be due to broader market conditions or investor sentiment. The long-term impact is likely positive as the company strengthens its European presence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100